We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B (BASIS KIDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05611801
Recruitment Status : Recruiting
First Posted : November 10, 2022
Last Update Posted : April 27, 2023
Sponsor:
Information provided by (Responsible Party):
Pfizer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients.

This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study will open enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years will be permitted to enroll. Lastly, children aged 1 to 5 years will be permitted to enroll.

This study will enroll participants who:

  • have severe Hemophilia A or moderately severe to severe Hemophilia B (with or without inhibitors)
  • have accurate historical records documenting all factor VIII, factor IX, or bypass agent infusions and hemophilia bleed events for at least 1 year prior to entering the study
  • if a non-inhibitor patient, must be on a stable routine prophylaxis regimen with factor VIII or factor IX replacement products for at least 12 months prior to study entry
  • if an inhibitor patient, must be on an on-demand bypass treatment regimen during the 12 months prior to study entry

All participants in this study will receive marstacimab to use prophylactically. Marstacimab will be given once a week as a subcutaneous (under the skin) shot. The first dose of marstacimab will be given at the study site by the study site staff. During the 12-month treatment period, weekly doses of marstacimab can be given at home, or if preferred, the doses may be given by the study site staff.

To help us determine if the study medicine is safe and effective, we will compare participant experiences when they are taking the study medicine to a historical period when they were not. Researchers want to see if the study medicine works to prevent the bleeding episodes commonly experienced by patients with Hemophilia.

Participants will be in this study for about 14 months (approximately 1 month in a Screening period, 12 months receiving treatment, and 1 month in a follow-up period) during which they will visit the study site at least 10 times. If preferred, and if local regulations allow it, 2 of the study visits can be completed at the participant's home instead of at the study site. There will also be 6 scheduled telephone calls approximately every 2 months.


Condition or disease Intervention/treatment Phase
Hemophilia A Hemophilia B Drug: marstacimab Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY =2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS
Actual Study Start Date : December 9, 2022
Estimated Primary Completion Date : September 10, 2028
Estimated Study Completion Date : September 10, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: marstacimab (PF-06741086)
Weekly subcutaneous injections.
 Drug: marstacimab
marstacimab
Other Name: PF-06741086


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Annualized bleeding rate (ABR) of treated bleeding events [ Time Frame: Baseline to end of 12-month treatment period ]
    Derived for each subject for each period (historical and study treatment) by using the following formula: ABR = number of bleeds requiring treatments/ (days on treatment period / 365.25)

  2. Incidence of adverse events and serious adverse events [ Time Frame: Screening through end of follow-up period (approximately 14 months) ]
  3. Incidence and severity of thrombotic events [ Time Frame: Baseline to end of 12-month treatment period ]
  4. Incidence and severity of thrombotic microangiopathy [ Time Frame: Baseline to end of 12-month treatment period ]
  5. Incidence and severity of disseminated intravascular coagulation/consumption coagulopathy events [ Time Frame: Baseline to end of 12-month treatment period ]
  6. Immunogenicity (incidence of ADA and clinically significant persistent NAb against marstacimab) [ Time Frame: Baseline to end of 12-month treatment period ]
  7. Incidence and severity of injection site reaction [ Time Frame: Baseline to end of 12-month treatment period ]
  8. Incidence of severe hypersensitivity and anaphylactic reactions [ Time Frame: Baseline to end of 12-month treatment period ]

Secondary Outcome Measures :
  1. Incidence of joint bleeds (treated) [ Time Frame: Baseline to end of 12-month treatment period ]
  2. Incidence of spontaneous bleeds (treated) [ Time Frame: Baseline to end of 12-month treatment period ]
  3. Incidence of target joint bleeds (treated) [ Time Frame: Baseline to end of 12-month treatment period ]
  4. Incidence of total bleeds (treated and untreated) [ Time Frame: Baseline to end of 12-month treatment period ]
  5. Number of target joints [ Time Frame: Baseline to end of 12-month treatment period ]
  6. Change from baseline in joint health as measured by the HJHS for participants ≥4 years of age [ Time Frame: Baseline to end of 12-month treatment period ]
  7. Changes in quality of life measured by Haem-A-QoL/Haemo-QoL (using age-dependent versions for participants ≥8 years of age) [ Time Frame: Baseline to end of 12-month treatment period ]
  8. Changes in quality of life measured by pedHAL (using age-dependent versions for participants ≥4 years of age) [ Time Frame: Baseline to end of 12-month treatment period ]
  9. Changes in quality of life measured by Patient Global Impression of Change - Hemophilia for participants ≥4 years of age [ Time Frame: Baseline to end of 12-month treatment period ]
  10. Changes in quality of life measured by Health Utilities Measure (EQ-5D-Y) for participants ≥4 years of age [ Time Frame: Baseline to end of 12-month treatment period ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male participants of appropriate age and required minimum weight
  • Participants aged 12 to 17 years must be at least 25 kgs at time of consent.
  • Participants aged 6 to 11 years must be at least 19 kgs at time of consent.
  • Minimum weight requirement for participants aged 1 to 5 years is to be determined.
  • Participants with a diagnosis of severe hemophilia A or moderately severe to severe hemophilia B
  • Participants must have at least 1 year of diary and/or medical records available in which exogenous FVIII or FIX replacement or bypass agent infusions and hemophilic bleeding episodes were consistently documented over the 12 months prior to the time of consent.

Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following criteria:

  • No current detectable inhibitor and no documented history of inhibitors in the 5 years prior to consent
  • Must have at least 50 exposure days to FVIII/FIX replacement products
  • Must be at least 80% compliant with a stable routine prophylaxis regimen with FVIII/FIX replacement products, for at least 12 months prior to consent

Participants who are enrolled into the Inhibitor Cohort must also meet the following criteria:

  • Documentation of current high titer inhibitor (≥5 BU/mL); or current low titer inhibitor (<5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX recovery <60% of expected within previous 12 months prior to the time of consent
  • Participants who have documented inhibitors while on factor-replacement therapy but who do not meet the high quantitative inhibitor criteria described in the prior bullet at the time of screening (eg, participant with a previously documented high-titer inhibitor ≥5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX replacement may be considered for eligibility on a case-by-case basis with discussion and agreement from the Pfizer medical monitor.
  • Hemophilia A participants with on-demand treatment regimen with ≥12 bleeding episodes or hemophilia B participants with on-demand treatment regimen with ≥8 bleeding episodes (spontaneous or traumatic) necessitating treatment with bypass factor in the 12 months prior to informed consent
  • Participants must be on an on-demand bypass treatment regimen during the 12 months prior to informed consent

Exclusion Criteria:

  • Known coronary artery, thrombotic, or ischemic disease
  • Known planned surgical procedure during the planned study period
  • Known hemostatic defect other than hemophilia A or B
  • Abnormal hematology, renal or hepatic function laboratory results at screening
  • Other acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator
  • Individuals with known allergic reaction or hypersensitivity to hamster protein or other components of the study intervention
  • Current routine prophylaxis with bypassing agent, non-coagulation non-factor replacement therapy (eg, emicizumab), or any previous treatment with a gene therapy product for treatment of hemophilia
  • Participants with inhibitors who are being treated using a prophylaxis treatment regimen with a bypass agent, and, participants who have previously received non-factor-based hemophilia therapy (eg, fitusiran, concizumab, emicizumab) will be considered on a case-by-case basis, only after discussion and agreement between the investigator and the Pfizer medical monitor
  • Ongoing or planned use of ITI, or prophylaxis with FVIII or FIX replacement at any time after initiation of treatment with study intervention
  • Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 30 days (or as determined by local requirements) or 5 half-lives prior to study entry or during study participation
  • Previous exposure to marstacimab during participation in other marstacimab clinical studies
  • CD4 cell count ≤200/uL if HIV-positive
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05611801


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Show Show 17 study locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT05611801    
Other Study ID Numbers: B7841008
2022-500495-65-00 ( Registry Identifier: CTIS (EU) )
ANTI-TFPI PEDIATRIC STUDY ( Other Identifier: Alias Study Number )
First Posted: November 10, 2022    Key Record Dates
Last Update Posted: April 27, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Factor VIII Inhibitor
Factor IX Inhibitor
PF-06741086
Marstacimab
Anti-TFPI
Factor VIII
Factor IX
Inhibitors
Anti-Tissue Factor Pathway Inhibitor (TFPI)
Subcutaneous (sc)
Prophylaxis
 On-Demand
BASIS KIDS
Inhibitor
SC
Subcutaneous
Injection
On demand
aTFPI
Severe hemophilia
Severe bleeding
Hemophilia
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
 Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked